Recent Updates — AIMI

AIM ImmunoTech Inc. reported financial results for the quarter ended June 30, 2026, showing cash and cash equivalents of $9.9 million as of June 30, up from approximately $3.0 million at year-end 2025. The company incurred a net loss of approximately $3.8 million, or $0.43 per share, compared to a net loss of $2.8 million, or $3.68 per share, in the same period last year. Research and development expenses decreased to approximately $589,000 from $1.2 million, while general and administrative expenses increased to $2.9 million from $1.5 million. Operationally, AIM completed patient enrollment and dosing in its Phase 2 DURIPANC trial for metastatic pancreatic cancer using Ampligen combined with Imfinzi. The company anticipates clinical benefit data in Q1 2027 and overall survival data in Q3 2027, while maintaining compliance with NYSE American listing standards. AIM ImmunoTech Inc. is an immuno-pharmaceutical company focused on developing Ampligen for late-stage pancreatic cancer and infectious diseases.

AIM ImmunoTech Inc. entered into a Proposal Agreement with Sterling Pharma Solutions on July 31, 2026, to manufacture batches of PolyI and Poly C12U drug substances and transfer associated test methods at the manufacturer's UK facility. The estimated cost is approximately $1.5 million payable over 12 months, with products intended for ongoing clinical trials and a potential Phase 3 trial for metastatic pancreatic cancer. The filing also discloses notice deadlines for director nominations for the 2026 annual meeting. AIM ImmunoTech Inc. operates in the biotechnology industry, focusing on immunotherapy treatments.

AIM ImmunoTech Inc. mutually terminated its Equity Distribution Agreement with Maxim Group LLC, effective August 15, 2026, without incurring termination penalties. The agreement allowed the company to sell shares via at-the-market offerings from April 1, 2025, through July 31, 2026. During this period, the company sold 3,200,736 shares for aggregate gross proceeds of approximately $2.8 million. The termination prevents further share issuances under the existing agreement or related prospectus supplements. AIM ImmunoTech Inc. operates in the biotechnology industry, focusing on developing immunotherapies.

AIM ImmunoTech Inc. held a Special Meeting of Stockholders on July 15, 2026, where shareholders approved seven proposals. Key approvals include permission to issue more than 19.99% of outstanding common stock to comply with NYSE American rules regarding the exercise of Class H, Class I, and Class J warrants, as well as the conversion of two specific promissory notes dated February 16, 2024, and November 18, 2025. Additionally, stockholders approved a series of alternate amendments to the Certificate of Incorporation allowing the Board of Directors to implement a reverse stock split of up to a 1-for-25 ratio. The meeting also approved the ability to adjourn the meeting if necessary for further proxy solicitation. AIM ImmunoTech Inc. is a biotechnology company focused on developing cancer immunotherapies.